Results 131 to 140 of about 1,862,222 (185)

Organoids in pediatric cancer research

FEBS Letters, Volume 600, Issue 21, Page 3221-3240, November 2026.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Advanced Materials for Biologics Delivery to Brain Tumors

Advanced Materials, Volume 38, Issue 61, 2 November 2026.
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng, Yuxue Cao, Maria Kavallaris, Taskeen Janjua, Amirali Popat   +4 more
wiley   +1 more source

Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis

Arthritis &Rheumatology, Volume 78, Issue 11, Page 2189-2202, November 2026.
Systemic sclerosis–associated interstitial lung disease (SSc‐ILD) is one of the leading causes of morbidity and mortality in SSc, affecting up to three‐quarters of patients. The disease course is highly heterogeneous, ranging from indolent, nonprogressive forms to rapidly progressive pulmonary fibrosis (PPF).
Devis Benfaremo, Dinesh Khanna, Corrado Campochiaro, Vincent Cottin, Fabrizio Luppi, Marco Matucci‐Cerinic, Gianluca Moroncini, Yannick Allanore   +7 more
wiley   +1 more source

Phase 1 study of the Hedgehog pathway inhibitor sonidegib for steroid-refractory chronic graft-versus-host disease. [PDF]

Blood Adv, 2017
DeFilipp Z, Nazarian RM, El-Jawahri A, Li S, Brown J, Del Rio C, Smith M, Valles B, Ballen KK, McAfee SL, Rosenblatt J, Antin JH, Cutler CS, Chen YB.   +13 more
europepmc   +1 more source

Mechanisms of Tumor Cell Invasion: Insights From the Perspective of Epithelial‐to‐Mesenchymal Transition

Cell Biochemistry and Function, Volume 44, Issue 11, November 2026.
ABSTRACT Tumor invasion implies aberrantly increased cell motility, and is the first step of the cascade of events culminating in the development of distant metastases. The emergence of migratory capacity in epithelial carcinomas, consisting essentially of stationary cells, is linked to the activation of the epithelial‐to‐mesenchymal transition (EMT ...
Marcello Guarino
wiley   +1 more source

Semi-Mechanism-Based Population Pharmacokinetic Modeling of the Hedgehog Pathway Inhibitor Vismodegib. [PDF]

CPT Pharmacometrics Syst Pharmacol, 2015
Lu T, Wang B, Gao Y, Dresser M, Graham RA, Jin JY.   +5 more
europepmc   +1 more source

The Potential Role of Gut Microbiome Dysbiosis and Functional Reprogramming in Colorectal Liver Metastasis via the Gut–Liver Axis

Cancer Reports, Volume 9, Issue 11, November 2026.
ABSTRACT Background Colorectal liver metastasis (CRLM) is a leading cause of mortality in colorectal cancer (CRC), yet current surveillance often misses occult micrometastases, underscoring an urgent need for early non‐invasive biomarkers and mechanistic insights.
Yuejin Sheng, Xiaoyu Dai, Jiaqi Lu, Hao Zhang, Ping Cai   +4 more
wiley   +1 more source

Intravenous Lipopolysaccharide Challenge in Healthy Participants Reveals Pharmacodynamic Markers in Blood and Bone Marrow for Early‐Phase Oncology Drug Development

Clinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1301-1314, November 2026.
Demonstrating pharmacological effects in early‐phase oncology clinical trials remains challenging, largely due to the lack of robust pharmacodynamic markers. Lipopolysaccharide (LPS) is used as an immune challenge agent in healthy participants to study drugs for autoimmune conditions.
Igor Radanović, Ingrid Tomljanović, Wieke H. Grievink, Diana R. Pereira, Michelle Osse, Peter van Balen, Maria J. Juachon, Marieke L. de Kam, Lisa Pagan, Manon A.A. Jansen, Matthijs Moerland, Jacobus J. Bosch   +11 more
wiley   +1 more source

LncRNA A1BGAS1 Serves as a Tumor Suppressor in Non‐Small Cell Lung Cancer by Modulating the Expression of miR‐3942‐5P

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 11, November 2026.
This study verified the potential of A1BG‐AS1 to serve as a molecular biomarker for NSCLC prognosis. Mechanistically, A1BG‐AS1 exerts inhibitory effects on NSCLC cell proliferation, migration, and invasion and exerts a promoting effect on apoptosis via direct targeting and downregulation of miR‐3942‐5p.
Jiahui Du, Zhenhua Li, Chunqiang Wang, Xuexi Zhang   +3 more
wiley   +1 more source

Anticancer potential of berberine: Molecular pathways and current clinical trial perspectives

JSFA reports, Volume 6, Issue 11, Page 473-489, November 2026.
Abstract Cancer is constantly rising mortality rates due to its late prognosis, poor management, and expensive treatment. Multi‐sectoral approaches for cancer management include hygienic practices, synthetic drug exploitation, radiation therapy, and diet modifications.
Muhammad Maaz, Muhammad Tauseef Sultan, Muhammad Israr, Waqas Ahmad Khan, Fahad Tanveer, Muzzamal Hussain, Muhammad Imran, Ahmed Mujtaba, Anjuman Gul Memon, Muhammad Atif, Entessar Al Jbawi   +10 more
wiley   +1 more source